{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Miyata H"],"funding":["Core Research for Evolutional Science and Technology","Japan Agency for Medical Research and Development","Japan Society for the Promotion of Science"],"pagination":["795-806"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10992913"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["71(4)"],"pubmed_abstract":["Recent studies have revealed that treatment-resistant cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) can be targeted by cytotoxic T lymphocytes (CTLs). CTLs recognize antigenic peptides derived from tumor-associated antigens; thus, the identification of tumor-associated antigens expressed by CSCs/CICs is essential. Human leucocyte antigen (HLA) ligandome analysis using mass spectrometry enables the analysis of naturally expressed antigenic peptides; however, HLA ligandome analysis requires a large number of cells and is challenging for CSCs/CICs. In this study, we established a novel bladder CSC/CIC model from a bladder cancer cell line (UM-UC-3 cells) using an ALDEFLUOR assay. CSCs/CICs were isolated as aldehyde dehydrogenase (ALDH)-high cells and several ALDH<sup>high</sup> clone cells were established. ALDH<sup>high</sup> clone cells were enriched with CSCs/CICs by sphere formation and tumorigenicity in immunodeficient mice. HLA ligandome analysis and cap analysis of gene expression using ALDH<sup>high</sup> clone cells revealed a distinctive antigenic peptide repertoire in bladder CSCs/CICs, and we found that a glutamate receptor, ionotropic, kainite 2 (GRIK2)-derived antigenic peptide (LMYDAVHVV) was specifically expressed by CSCs/CICs. A GRIK2 peptide-specific CTL clone recognized GRIK2-overexpressing UM-UC-3 cells and ALDH<sup>high</sup> clone cells, indicating that GRIK2 peptide can be a novel target for bladder CSC/CIC-targeting immunotherapy."],"journal":["Cancer immunology, immunotherapy : CII"],"pubmed_title":["GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy."],"pmcid":["PMC10992913"],"funding_grant_id":["JPMJCR15G3","17H01540","16770510","20cm0106352h0002","20H03460"],"pubmed_authors":["Kanaseki T","Tsukahara T","Yamada S","Hori K","Miyata H","Murai A","Yanagawa J","Shinohara N","Kubo T","Tokita S","Hashimoto S","Torigoe T","Hirohashi Y","Abe T"],"additional_accession":[]},"is_claimable":false,"name":"GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.","description":"Recent studies have revealed that treatment-resistant cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) can be targeted by cytotoxic T lymphocytes (CTLs). CTLs recognize antigenic peptides derived from tumor-associated antigens; thus, the identification of tumor-associated antigens expressed by CSCs/CICs is essential. Human leucocyte antigen (HLA) ligandome analysis using mass spectrometry enables the analysis of naturally expressed antigenic peptides; however, HLA ligandome analysis requires a large number of cells and is challenging for CSCs/CICs. In this study, we established a novel bladder CSC/CIC model from a bladder cancer cell line (UM-UC-3 cells) using an ALDEFLUOR assay. CSCs/CICs were isolated as aldehyde dehydrogenase (ALDH)-high cells and several ALDH<sup>high</sup> clone cells were established. ALDH<sup>high</sup> clone cells were enriched with CSCs/CICs by sphere formation and tumorigenicity in immunodeficient mice. HLA ligandome analysis and cap analysis of gene expression using ALDH<sup>high</sup> clone cells revealed a distinctive antigenic peptide repertoire in bladder CSCs/CICs, and we found that a glutamate receptor, ionotropic, kainite 2 (GRIK2)-derived antigenic peptide (LMYDAVHVV) was specifically expressed by CSCs/CICs. A GRIK2 peptide-specific CTL clone recognized GRIK2-overexpressing UM-UC-3 cells and ALDH<sup>high</sup> clone cells, indicating that GRIK2 peptide can be a novel target for bladder CSC/CIC-targeting immunotherapy.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2026-06-02T02:13:31.991Z","creation":"2026-04-13T03:12:47.353Z"},"accession":"S-EPMC10992913","cross_references":{"pubmed":["34405274"],"doi":["10.1007/s00262-021-03025-z"]}}